An update from Aerovate Therapeutics (AVTE) is now available.
Aerovate Therapeutics recently announced disappointing results from their Phase 2b IMPAHCT study, which assessed the efficacy of AV-101 in treating Pulmonary Arterial Hypertension. The drug failed to meet the primary endpoint and showed no significant improvement in the secondary endpoint of walking distance. Consequently, the company has decided to halt the Phase 3 study and a long-term extension study. Despite this setback, Aerovate maintains a cash reserve of around $100 million.
For a thorough assessment of AVTE stock, go to TipRanks’ Stock Analysis page.
